首页> 外文期刊>American Journal of Dermatopathology >Tissue microarray analysis of ezrin, KBA.62, CD166, nestin, and p-Akt in melanoma versus banal and atypical nevi, and nonmelanocytic lesions.
【24h】

Tissue microarray analysis of ezrin, KBA.62, CD166, nestin, and p-Akt in melanoma versus banal and atypical nevi, and nonmelanocytic lesions.

机译:黑色素瘤与非典型和非典型痣以及非黑素细胞病变的ezrin,KBA.62,CD166,nestin和p-Akt的组织微阵列分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Multiple melanocytic markers are useful for differentiating between melanoma and nonmelanocytic lesions but generally do not distinguish melanoma from nevi and atypical melanocytic lesions. We sought to determine if several immunohistochemical markers recently described in the literature, including ezrin, KBA.62, p-Akt, CD166, and nestin, may be helpful in distinguishing these lesions. One hundred ten tissue microarray samples were scored for nestin and CD166 and 220 samples for ezrin, KBA.62, and p-Akt. We found that putative stem cell markers nestin and CD166 were both expressed in most melanomas (86% and 65% of samples, respectively), including desmoplastic melanoma, but were also expressed at similar levels in nevi (79% and 74%, respectively). In addition, these markers were not specific for melanocytic lesions. Ezrin was also expressed in both nevi and melanoma (81% each), including desmoplastic melanoma (75%), and in neural tumors. KBA.62 stained more cases of nevi versus melanoma (93% and 65%, respectively) and was positive in 53% of desmoplastic melanoma. However, it was also positive in several nonmelanocytic tumors. P-Akt expression was generally weak but was increased in nevi (75%) versus melanoma (43%), and was lost in desmoplastic melanomas (5%). Overall, only KBA.62 and p-Akt expression differed between melanoma and nevi, and none of these markers were completely specific for melanocytic tumors versus nonmelanocytic lesions.
机译:多种黑素细胞标记物可用于区分黑素瘤和非黑素细胞病变,但通常不能将黑素瘤与痣和非典型黑素细胞病变区分开。我们试图确定最近在文献中描述的几种免疫组织化学标记物,包括ezrin,KBA.62,p-Akt,CD166和nestin,是否可能有助于区分这些病变。对一百一十个组织微阵列样品的巢蛋白和CD166评分,对220个样品的ezrin,KBA.62和p-Akt评分。我们发现推定的干细胞标志物Nestin和CD166都在大多数黑色素瘤(分别占样本的86%和65%)中表达,包括在增生性黑色素瘤中也有相似的表达水平(分别为79%和74%)。 。另外,这些标记物对黑素细胞性病变不是特异性的。 Ezrin在痣和黑色素瘤(各占81%)(包括增生性黑色素瘤(75%))和神经肿瘤中也表达。与黑色素瘤相比,KBA.62染色的痣病例更多(分别为93%和65%),而在增生性黑色素瘤中53%呈阳性。但是,它在一些非黑素细胞肿瘤中也呈阳性。 P-Akt表达通常较弱,但在痣(75%)相对于黑色素瘤(43%)有所增加,而在增生性黑色素瘤(5%)中却消失了。总体而言,黑色素瘤和痣之间只有KBA.62和p-Akt表达有所不同,而且这些标记物对黑素细胞瘤和非黑素细胞病变均没有完全特异性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号